THE TAPE
HAE · Medical Instruments · $5.5B

Haemonetics Corporation

$121.34▼ −1.30%
Last close
Relative strength
95RS
of 99, against every stock▼ -3 on the month
Cooling off
Unconfirmed
+61.4%
six months against Medical Instruments
52-week range
−8.1%
from the high
$51.00$132.00
Setup
blue skyclimbing
−2.0%
against the pivot at $123.77
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 26, revenue +9% on a year ago
11/16 O 123.74 H 124.13 L 120.67 Vol 365.9K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS95
vs pivot−1.96%
Tightening1.43×
Dry-up0.93×
Up/down vol0.09
From high8%
failed pokeclimbing8 of 9checks
Cooling off
Support and resistance
Support below
$110.10
-9.3% · tested 3× · last 38 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 3.2 weeks and fell 7% from its ceiling at its deepest. The pivot is $123.77, and the stock closed 2.0% below it. Its relative strength rating is 95.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-1.5%
Three months against its industry
+15.8%
Six months against its industry
+61.4%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Also on
Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 14.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$1.4B
+9.3% year on year
Operating margin
12.8%
gross 59.6%
Net margin
0.5%
Free cash flow
$298.2M
5.4% of market cap
Price to sales
3.99×
Price to earnings
824.3×

Twelve months to Sep 26, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 5
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$357.8M
+5.4% QoQ · +9.3% YoY
Gross margin
61.7%
+1.9 pts QoQ
Net income
$46.3M
Positive
Free cash flow
$113.3M
Cash generating

What the numbers say

  • Revenue +9.3% year over year, +5.4% on the quarter
  • Good: Gross margin 61.7%, +1.9 points on the quarter
  • Good: Profitable: net income $46M, operating margin 21.0%
  • Good: Cash generating: operating cash flow $128M, free cash flow $113M
  • Good: Share count -2.5% in a year: buying back
  • Weak: Net debt $863M · cash $261M
Revenue by quarter
Free cash flow
Net income
shares -2.5% in a year · net debt $863.0M

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is the balance sheet: net debt $863M · cash $261M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Reported resultsFiling · 2026-11-11
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Pulled back while its group leadsTape · 2026-11-10
3 lower closes in a leading group, 50d held, at 118.21
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-06
above 20d & 50d on 1.9x volume at 124.11
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-05
+5.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-05
+5.9% on earnings 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Earnings comingEvent · 2026-11-03
reports 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
New 52-week highTape · 2026-10-09
4.8x vol
Mixed: stocks have lagged random stocks by 0.9% over three sessions, not consistently enough to call (554 cases over 52 nights). Against their own sector they have lagged by 2.1%.
GappedTape · 2026-10-09
+17.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
1
$101,148 total

Sold: Maunsell Farris Maryanne.

Not counted above: 15 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-11 Maunsell Farris Maryanne · VP, Chief Accounting Officeroption exercise1,068$95,223
2026-11-11 Maunsell Farris Maryanne · VP, Chief Accounting Officeroption exercise645$61,746
2026-11-11 Maunsell Farris Maryanne · VP, Chief Accounting Officeroption exercise433$30,444
2026-11-11 Maunsell Farris Maryanne · VP, Chief Accounting Officerwithheld for tax1,724$208,776
2026-11-11 Maunsell Farris Maryanne · VP, Chief Accounting Officersell836$101,148
2026-10-30 Galvin Roy · EVP, Chief Commercial Officerwithheld for tax146$17,469
2026-07-24 Madaus Martin D · Directoraward2,538
2026-07-24 Zane Ellen M · Directoraward2,538

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$126.08
Wrong below$115.62
Measured target · a squeeze has no height to projectnone
Through to the apex36%
Leaning · and strengtheningup
Length1.0 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

8 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy4
Buy6
Hold2
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
3w · 7%

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Haemonetics Corporation (HAE) — The Tape